173 related articles for article (PubMed ID: 38526966)
1. Neuroprotective effect of green tea extract (-)-epigallocatechin-3-gallate in a preformed fibril-induced mouse model of Parkinson's disease.
Shen J; Xie J; Ye L; Mao J; Sun S; Chen W; Wei S; Ruan S; Wang L; Hu H; Wei J; Zheng Y; Xi Z; Wang K; Xu Y
Neuroreport; 2024 Apr; 35(6):421-430. PubMed ID: 38526966
[TBL] [Abstract][Full Text] [Related]
2. Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral α-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys.
Chen M; Wang T; Yue F; Li X; Wang P; Li Y; Chan P; Yu S
Neuroscience; 2015 Feb; 286():383-92. PubMed ID: 25498223
[TBL] [Abstract][Full Text] [Related]
3. Epigallocatechin Gallate Has a Neurorescue Effect in a Mouse Model of Parkinson Disease.
Xu Q; Langley M; Kanthasamy AG; Reddy MB
J Nutr; 2017 Oct; 147(10):1926-1931. PubMed ID: 28835392
[No Abstract] [Full Text] [Related]
4. Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.
Merghani MM; Ardah MT; Al Shamsi M; Kitada T; Haque ME
Neurotoxicology; 2021 May; 84():41-52. PubMed ID: 33549656
[TBL] [Abstract][Full Text] [Related]
5. Epigallocatechin gallate protects dopaminergic neurons against 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by inhibiting microglial cell activation.
Li R; Peng N; Du F; Li XP; Le WD
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Apr; 26(4):376-80. PubMed ID: 16624731
[TBL] [Abstract][Full Text] [Related]
6. Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate.
Choi JY; Park CS; Kim DJ; Cho MH; Jin BK; Pie JE; Chung WG
Neurotoxicology; 2002 Sep; 23(3):367-74. PubMed ID: 12387363
[TBL] [Abstract][Full Text] [Related]
7. Investigating the potential effects of α-synuclein aggregation on susceptibility to chronic stress in a mouse Parkinson's disease model.
Alwani A; Maziarz K; Burda G; Jankowska-Kiełtyka M; Roman A; Łyszczarz G; Er S; Barut J; Barczyk-Woźnicka O; Pyza E; Kreiner G; Nalepa I; Chmielarz P
Pharmacol Rep; 2023 Dec; 75(6):1474-1487. PubMed ID: 37725330
[TBL] [Abstract][Full Text] [Related]
8. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
[TBL] [Abstract][Full Text] [Related]
9. (-)-Epigallocatechin-3-gallate modulates peripheral immunity in the MPTP-induced mouse model of Parkinson's disease.
Zhou T; Zhu M; Liang Z
Mol Med Rep; 2018 Apr; 17(4):4883-4888. PubMed ID: 29363729
[TBL] [Abstract][Full Text] [Related]
10. Reelin protects against pathological α-synuclein accumulation and dopaminergic neurodegeneration after environmental enrichment in Parkinson's disease.
Cho E; Kim K; Kim H; Cho SR
Neurobiol Dis; 2022 Dec; 175():105898. PubMed ID: 36270619
[TBL] [Abstract][Full Text] [Related]
11. Epigallocatechin Gallate Destabilizes α-Synuclein Fibril by Disrupting the E46-K80 Salt-Bridge and Inter-protofibril Interface.
Yao Y; Tang Y; Wei G
ACS Chem Neurosci; 2020 Dec; 11(24):4351-4361. PubMed ID: 33186020
[TBL] [Abstract][Full Text] [Related]
12. Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases.
Gonçalves PB; Sodero ACR; Cordeiro Y
Biomolecules; 2021 May; 11(5):. PubMed ID: 34065606
[TBL] [Abstract][Full Text] [Related]
13. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
Patterson JR; Duffy MF; Kemp CJ; Howe JW; Collier TJ; Stoll AC; Miller KM; Patel P; Levine N; Moore DJ; Luk KC; Fleming SM; Kanaan NM; Paumier KL; El-Agnaf OMA; Sortwell CE
Neurobiol Dis; 2019 Oct; 130():104525. PubMed ID: 31276792
[TBL] [Abstract][Full Text] [Related]
14. [Neuroprotective effect of cinnamaldehyde in MPTP-induced mouse model of subacute Parkinson's disease].
Wu SH; Shi YJ; An YF; Zhao DD; Li HB; Li GL
Zhongguo Zhong Yao Za Zhi; 2022 Dec; 47(23):6485-6493. PubMed ID: 36604895
[TBL] [Abstract][Full Text] [Related]
15. Deficits in basal and evoked striatal dopamine release following alpha-synuclein preformed fibril injection: An in vivo microdialysis study.
Centner A; Del Priore I; Chambers N; Cohen SR; Terry ML; Coyle M; Glinski J; Stoll AC; Patterson JR; Kemp CJ; Miller KM; Kubik M; Kuhn N; Luk KC; Sortwell CE; Bishop C
Eur J Neurosci; 2024 Apr; 59(7):1585-1603. PubMed ID: 38356120
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of osmotin in Parkinson's disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways.
Park JS; Choe K; Lee HJ; Park TJ; Kim MO
J Biomed Sci; 2023 Aug; 30(1):66. PubMed ID: 37568205
[TBL] [Abstract][Full Text] [Related]
17. MLKL deficiency alleviates neuroinflammation and motor deficits in the α-synuclein transgenic mouse model of Parkinson's disease.
Geng L; Gao W; Saiyin H; Li Y; Zeng Y; Zhang Z; Li X; Liu Z; Gao Q; An P; Jiang N; Yu X; Chen X; Li S; Chen L; Lu B; Li A; Chen G; Shen Y; Zhang H; Tian M; Zhang Z; Li J
Mol Neurodegener; 2023 Dec; 18(1):94. PubMed ID: 38041169
[TBL] [Abstract][Full Text] [Related]
18. α-Synuclein A53T Binds to Transcriptional Adapter 2-Alpha and Blocks Histone H3 Acetylation.
Lee JY; Kim H; Jo A; Khang R; Park CH; Park SJ; Kwag E; Shin JH
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065515
[TBL] [Abstract][Full Text] [Related]
19. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
Mandel S; Maor G; Youdim MB
J Mol Neurosci; 2004; 24(3):401-16. PubMed ID: 15655262
[TBL] [Abstract][Full Text] [Related]
20. α-Synuclein Propagation Mouse Models of Parkinson's Disease.
Uemura N; Ueda J; Okuda S; Sawamura M; Takahashi R
Methods Mol Biol; 2021; 2322():119-130. PubMed ID: 34043198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
